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The treatment of diseases affecting the posterior segment of the eye is limited by the difficulty in 
transporting effective doses of drugs to the vitreous, retina, and choroid. Topically applied drugs are 
poorly absorbed due to the low permeability of the external ocular tissues and tearing. The blood-retina 
barrier limits drug diffusion from the systemic blood to the posterior segment, thus high doses of drug 
are needed to maintain therapeutic levels. In addition, systemic side effects are common. Intraocular 
injections could be an alternative, but the fast flowing blood supply in this region, associated with rapid 
clearance rates, causes drug concentration to quickly fall below therapeutic levels. To obtain therapeutic 
levels over longer time periods, polymeric sustained-drug release systems implanted within the vitreous 
are being studied for the treatment of vitreoretinal disorders. These systems are prepared using different 
kinds of biodegradable or non-biodegradable polymers. This review aims to demonstrate the main 
characteristics of these drug delivery implants and their potential for clinical application.
Uniterms: Implants/biodegradation. Drugs/delivery systems. Drugs/prolonged delivery systems. 
Pharmaceutical technology.
O tratamento de doenças do segmento posterior do olho é limitado pela dificuldade no transporte de 
doses efetivas de fármacos para o vítreo, retina e coróide. Os fármacos aplicados topicamente são 
pouco absorvidos por causa da baixa permeabilidade dos tecidos oculares externos e ao lacrimejamento. 
Embora a administração sistêmica seja capaz de transportar fármacos para o segmento posterior do olho, 
as barreiras hemato-aquosa e hematorretiniana dificultam a absorção e, normalmente, são necessárias 
doses elevadas, as quais estão geralmente associadas a potenciais efeitos adversos. Injeções intravitreais 
são capazes de transportar fármacos para o segmento posterior do olho, mas é uma técnica invasiva, 
pouco tolerada pelos pacientes e apresenta riscos de infecções oculares e danos aos tecidos. Visando 
a obtenção de níveis terapêuticos adequados de fármacos no segmento posterior do bulbo do olho por 
longos períodos, sistemas de liberação poliméricos implantados diretamente no vítreo estão sendo 
investigados para o tratamento de várias doenças vítreo-retinianas. Esses implantes podem ser preparados 
a partir de diferentes polímeros biocompatíveis, biodegradáveis ou não-biodegradáveis. Nesta revisão, 
as principais características destes implantes transportadores de fármacos são descritas, expondo suas 
potencialidades de aplicação clínica.
Unitermos: Implantes oculares/biodegradação. Fármacos/sistemas de liberação. Fármacos/ Fármacos/
ação prolongada. Tecnologia farmacêutica.
INTRODUCTION
In this paper, we present a review on biodegradable 
and non-biodegradable implants for the treatment of eye 
diseases which includes a discussion of the advantages 
and disadvantages of each type of implant.
Intraocular implants are controlled drug delivery 
systems prepared from biodegradable or non-biodegra-
dable polymers. Generally, these are introduced into the 
vitreous through an incision in the ocular pars plana, 
which is located posterior to the lens and anterior to the 
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retina. Despite the invasive characteristics of the implan-
tation technique, the implants present several advantages 
that outweigh the inconveniences of the implantation 
procedure. These advantages include: (1) the overcoming 
of the blood-retina barrier, allowing drug delivery at the-
rapeutic levels directly into the target site; (2) prolonged 
drug delivery; and (3) reduction of the side effects fre-
quently observed with intravitreal injections and systemic 
administration.
NON-BIODEGRADABLE IMPLANTS
Non-biodegradable polymeric implants can be 
presented in the form of matrix (monolithic) or reservoir 
systems. In the matrix system, the drug is dispersed, ho-
mogeneously, inside the polymeric matrix or adsorbed 
onto the surface. Slow diffusion of the drug through the 
matrix provides its controlled or sustained release. In 
the reservoir-type system, the drug is surrounded by a 
permeable non-degradable membrane whose thickness 
and permeability properties can control the diffusion of 
the drug into the body. The release kinetics of the drug 
from this system suggest that if the concentration of the 
drug within the reservoir is in constant equilibrium with 
the inner surface of the enclosed membrane, the driving 
force for diffusional release of the agent is constant, and 
zero order release kinetics of the drug from the delivery 
system is achieved. The drug-release rate is determined 
by different factors, such as the release area, the thickness 
of the polymeric membrane, the implant form, as well as 
drug solubility (Bourges et al., 2006).
The polymers most employed in the preparation of 
these implants include: silicon, polyvinyl alcohol (PVA) 
and ethylene vinyl acetate (EVA). Polymers, such as sili-
con and PVA, are easily permeable for a variety of lipo-
philic drugs due to their hydrophobic characteristics. EVA 
is impermeable to most drugs and is used as a membrane 
around the reservoir to reduce the rate of drug diffusion 
through the implant (Smith et al., 1992; Dash, Cudworth, 
1998; Yasukawa et al., 2004; Bourges et al., 2006).
Non-biodegradable implants in the treatment of 
cytomegalovirus retinitis
Cytomegalovirus retinitis (CMV) is the major ocular 
infection in acquired immune deficiency syndrome (AIDS) 
patients. Several studies have been carried out in an at-
tempt to develop non-biodegradable intraocular implants 
containing ganciclovir for the treatment of cytomegalo-
virus retinitis (Ashton et al., 1992; Martin et al., 1994 
Sanborn et al., 1992; Charles, Steiner, 1996). These studies 
were performed on animals and humans and, in 1996, led 
to the development of Vitrasert® (Bausch & Lomb, USA) 
and its approval by the Food and Drug Administration 
(FDA) (Bourges et al., 2006).
Vitrasert® is a controlled-release intraocular implant 
that contains 4.5mg of ganciclovir. This non-biodegradable 
implant is composed of a ganciclovir tablet surrounded by 
PVA/EVA. Vitrasert® was developed before the evolution 
of antiretroviral therapy, when patient life expectancy was 
approximately 12 months. Consequently, this precluded 
proper evaluation of possible complications that may stem 
from the use of the implant beyond this 12-month period. 
With the introduction of antiretroviral therapy, AIDS patient 
life expectancy increased significantly, and the treatment of 
CMV retinitis, as well as the complications associated with 
the use of the implant and the surgical procedure could be 
assessed over a longer period of time. Among the described 
complications, vitreous hemorrhage was the most common 
in both the implantation procedure and implant removal. 
Some complications, possibly related to the implant, were 
also reported, including: cataract, retinal detachment, 
vitreous hemorrhage, hypotony, epiretinal membrane, 
macular edema, and endophthalmitis. These complications 
were observed during the first two years of implantation in 
a way that suggested their incidence was associated with 
several factors and not only with the presence of the implant. 
Briefly, the results of this research, carried out between 
1995 and 2001, suggested that the complications directly 
related to the implantation procedure or to the presence of 
the implant in the eye, are not very common but can occur 
within a 7-year period, thus indicating the need to carefully 
select cases in which the implant should be used. It was also 
observed that the continuous use of the implant associated 
with the antiretroviral therapy could in fact reduce vision 
loss, as it was able to treat CMV retinitis (Kapel et al., 2006).
Non-biodegradable implants in the treatment of 
uveitis
Uveitis is originally used to describe ocular inflam-
mation of the uvea, though it can also be used to describe 
inflammations in the retina, the optical nerve, and the 
vitreous (Herrero-Vanrell, Refojo, 2001). The treatment 
of infectious or non-infectious uveitis requires pharma-
cological therapy with steroids, immunosuppressives, 
antibiotics, or all these drugs combined, to suppress 
chronic inflammatory processes or, in specific cases, to 
prevent recurrence (Yasukawa et al., 2004). These uveal 
inflammations can reduce visual acuity and promote vision 
loss. The potential of intraocular implants with controlled 
drug release to reduce these effects has been evaluated.
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Retisert® is an intraocular implant that contains 
fluocinolone acetonide (FA), developed and commercia-
lized by Bausch & Lomb, to treat non-infectious uveitis, 
which affects the posterior segment of the eye. Retisert® 
is composed of an FA tablet containing microcrystalline 
cellulose, magnesium stearate, and PVA (Figure 1). This 
tablet presents a silicone elastomer coating containing a 
release orifice. A semi-permeable layer of PVA is positio-
ned between the tablet and the release orifice to create a 
drug release diffusion barrier. Clinical studies carried out 
on patients with severe non-infectious uveitis demonstra-
ted the efficacy of Retisert®, where the FA released over a 
period of approximately 30 months significantly reduced 
the recurrence of the disease, increased visual acuity and 
reduced the need of supplementary topical, systemic, and 
periocular therapies. Progression of cataract and increase 
in intraocular pressure (IOP) were the main side effects 
related to the use of Retisert® (Jaffe et al., 2006).
Studies carried out by Debra and coworkers showed 
that the incidence and magnitude of the increase in IOP 
were significant in the eyes receiving the implant, which 
required subsequent pharmacological treatment or sur-
gical procedures to reduce the IOP (Debra et al., 2007). 
Therefore, patients must be aware of the possibility of 
an increase in IOP and must be prepared for the constant 
monitoring of IOP as well as for the significant risks of 
developing glaucoma.
Other studies have been carried out in an attempt 
to develop intraocular non-biodegradable devices for the 
controlled release of drugs to treat non-infectious uveitis. 
These studies are described below.
Cheng et al. prepared non-biodegradable implants 
for the sustained release of dexamethasone for the tre-
atment of experimental uveitis in rabbit eyes (Cheng et 
al., 1995). These implants were effective in suppressing 
induced inflammation and released the drug for approxi-
mately 105 days.
Jaffe et al. developed PVA/EVA implants for the 
intravitreal administration of cyclosporin A (CsA) for the 
treatment of experimental uveitis in rabbit eyes (Jaffe et 
al., 1998). The histology showed that the untreated eyes 
presented exacerbated inflammation and a disarrangement 
of retinal cell layers, while the eyes that received the im-
plants containing CsA presented a significant decrease in 
inflammation and preserved retinal structure. Furthermore, 
the implants released the drug at therapeutic levels for at 
least 6 months with no detection of the drug in the blood 
stream.
Okabe and coworkers developed PVA/EVA implants 
for intrascleral application and the controlled release of 
betamethasone (Okabe et al., 2003). The implants released 
the drug for 4 weeks with no significant toxic reactions ob-
served in electroretinographic evaluations or histological 
studies carried out on rabbit eyes. These results suggest 
that the intrascleral route can also be used for the implan-
tation of the controlled release of drugs for the treatment 
of posterior uveitis.
Non-biodegradable implants in the treatment of 
diabetic retinopathy
Diabetic retinopathy is the second most prevalent 
cause of blindness in adults in the western world, repre-
senting approximately 19% of blindness cases. Diabetic 
maculopathy, in which macular edema is the main sign, 
is the most frequent cause of significant visual loss in 
diabetics, with a prevalence of 18% to 20% in type I and 
type II diabetics, respectively. The visual loss promoted 
FIGURE 1 - Schematic representation of Retisert® (http://www.retisert.com/professional_delivery.html).
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by diabetes can be avoided or reduced with appropriate 
clinical control as well as through use of local and syste-
mic treatments. In diabetic retinopathy, the rupture of the 
retinal-blood barrier allows the release of liquids and plas-
matic components (mainly lipoproteins) into the interstitial 
space of the retina, leading to the formation of edemas. 
Edemas can be focal or diffuse and appear clinically as a 
thick and opacified retina (Motta et al., 2008).
The treatment of diabetic retinopathy and, conse-
quently, of diabetic macular edema, should be perfor-
med using different approaches aimed at prevention, 
intervention, and restoration. In preventive treatment, 
hypoglycemic and antihypertensive drugs should be 
used whilst intravitreal steroids and anti-angiogenic and 
antiproliferative drugs should be used for interventions. 
Finally, restorations require surgical procedures (Ávila, 
2003).
Non-biodegradable implants containing fluocinolo-
ne acetonide for the treatment of diabetic macular edema 
are being assessed in phase III clinical studies. These im-
plants, called Iluvien® (Alimera Sciences Products), are 
small tubes measuring 3.5mm in length and 0.37mm in 
diameter which can be inserted into the vitreous by injec-
tion and need no surgical procedures. They can promote 
controlled release of fluocinolone acetonide for 24 to 36 
months (Kane et al., 2008).
Non-biodegradable implants containing cells in 
the treatment of retinal diseases
Recently, MacDonald et al. (2007) demonstrated a 
new therapeutic approach for the treatment of retinal di-
seases in humans (phase I clinical studies). This approach 
involves a non-biodegradable intraocular implant contai-
ning encapsulated cells that are able to produce ciliary 
neurotrophic factor (CNTF). CNTF is a member of the 
interleukin-6 family of proteins which acts by binding a 
receptor complex consisting of the CNTF receptor alpha 
(CNTFR-a) and two others receptors. CNTFR-a has been 
localized in retinal pigment epithelial cells, rods and cones, 
inner nuclear cells, as well as retinal ganglion cells and 
their axons. When bound to its receptor complex, CNTF 
activates the extracellular signal-regulated kinase pathway, 
present in both rods and cones, thus inducing neuropro-
tection. Patients with retinitis pigmentosa who received 
these intravitreal implants presented an improvement in 
visual acuity. Furthermore, the implants did not produce 
side effects, such as increased IOP, retinal detachment, 
infection, or severe inflammation. Moreover, the implant 
cells released CNTF at therapeutic levels for 6 months. 
The results from this research call for further phase II and 
phase III clinical studies to investigate whether or not 
CNTF can stabilize or improve visual functions.
BIODEGRADABLE IMPLANTS
The implants containing biodegradable polymers 
can also be of two types: matricial (monolithic) and 
reservoir systems. In the matricial system, the polymer 
degrades slowly under physiological conditions, and the 
drug is released during polymer degradation. In this case, 
the drug can also be released by diffusion through the ma-
trix pores. In reservoir systems, the membrane generally 
degrades slower than in drug diffusion (Dash, Cudworth, 
1998; Fialho et al., 2003).
A wide variety of natural and synthetic biodegrada-
ble polymers have been investigated for the development 
of implants. Natural polymers, such as bovine serum al-
bumin, human serum albumin, collagen, and gelatin have 
been studied for drug delivery. However, the use of these 
polymers is limited due to their higher cost and questio-
nable purity. Synthetic polymers, such as poly(amides), 
poly(amino acids), poly(alkyl-a-cyano acrylates), 
poly(esters), poly(orthoesters), poly(urethanes), and 
poly(acrylamides) have been increasingly used to deliver 
drugs as they are devoid of most of the problems associa-
ted with natural polymers (Jain, 2000). Of this group of 
polymers, the thermoplastic aliphatic poly(esters) such 
as PLA, PGA, and especially PLGA, have been the most 
studied. The polymers and copolymers derived from the 
lactide and glycolide acids (PGA, PLA, and PLGA) are 
aliphatic polyesters that can be degraded by enzymatic 
or non-enzymatic hydrolysis. The ester bonds of these 
polymers are susceptible to hydrolytic degradation under 
physiological conditions. In addition, the degradation pro-
ducts formed (lactic and glycolic acids) are metabolized 
into carbon dioxide and water through the Krebs cycle 
(Chandra, Rustgi, 1998; Yasukawa et al., 2005).
Poly(e-caprolactone) (PLC) is a semi-crystalline and 
hydrophobic polyester, formed from the polymerization of 
e-caprolactone monomers. PCL degrades through hydroly-
sis due to ester bonds. However, the degradation rate of 
PCL is slow (2 to 3 years) (Bourges et al., 2006; Nair, 
Laurencin, 2007). The slow degradation, high biocompati-
bility, and high permeability of drugs are characteristics of 
PCL that have been investigated to develop controlled drug 
delivery devices in the eye (Kimura, Ogura, 2001; Dong 
et al., 2006; Peyman, Ganiban, 2006; Fialho et al., 2008).
Poly(ortho esters) (POE) are hydrophobic biode-
gradable polymers specially developed for controlled 
drug release. Since 1970, four families of POE have been 
investigated in biomedical applications. POE I and POE II 
Implants as drug delivery devices for the treatment of eye diseases 589
families are not currently used in ophthalmology. POE III 
presents polymeric, highly flexible chains that form a gel at 
room temperature. The viscous nature of this polymer allo-
ws the incorporation of therapeutic substances without the 
use of organic solvents. Moreover, POE III can be injected 
directly into the eye using appropriate needles (Bourges 
et al., 2006; Nair, Laurencin, 2007). The intracameral and 
intravitreal biocompatibility of POE II has been extensive-
ly investigated. Intracameral biocompatibility was found 
to be dependent on the amount of polymer injected into 
the anterior chamber. When 50 µL was administered, the 
polymer degraded in two weeks. The clinical results also 
demonstrated good biocompatibility of POE III, with no 
toxicity of the ocular tissues or increase in IOP. The injec-
tion of greater volumes proved to be inappropriate as the 
direct contact of the material with the corneal endothelium 
caused a reversible edema and inflammation in the anterior 
chamber, which reduced after several days. The intravitreal 
administration of POE III was well tolerated where the 
polymer degraded slowly in the vitreous and no inflam-
matory process occurred (Einmahl et al., 2000). POE IV 
presented significant degradation due to the incorporation 
of lactide and glycolide acids in the polymeric matrix. The 
degradation rate can vary from days to months depending 
on the proportion of the acids incorporated. Studies carried 
out by Einmahl and coworkers demonstrated the biocom-
patibility of POE IV after subconjunctival injection, with 
complete degradation of the polymer within approximately 
5 weeks (Einmahl et al., 2002; Einmahl et al., 2003). After 
intravitreal and suprachoroidal injection, the polymer de-
graded in approximately 3 and 6 months, respectively, and 
the biocompatibility was excellent with no inflammatory 
reactions. Despite the advantageous characteristics of POE 
III and IV in ocular applications, the difficulty in producing 
polymers on an industrial scale limits their use.
Biodegradable implants in the treatment of 
cytomegalovirus retinitis
Kunou and coworkers (1995) developed biode-
gradable implants made from PLGA (75:25) and 25% 
of ganciclovir for the treatment of CMV retinitis. These 
implants presented a triphasic drug release profile. In the 
first phase, approximately 40% of the drug was released 
within one week. In the diffusional phase, about 10% of 
ganciclovir was released in 8 weeks, whereas in the final 
phase, approximately 100% of the drug was released 
within 4 weeks. Due to the non-enzymatic hydrolysis of 
PLGA, the implant completely disappeared after 5 months.
The main disadvantages of implants prepared with 
lactide and glycolide acids copolymers include: 1) the 
release of large amounts of the drug (overdose) in the final 
phase and 2) the difficulty of prolonging and increasing 
drug release rates in the diffusional phase. To reduce these 
complications, Kunou and coworkers developed implants 
containing PLA blends with different molecular weights 
(70-kDa and 50-kDa), at the proportion of 80:20 (Kunou et 
al., 2000). These systems promoted a more homogeneous 
release of ganciclovir in the final phase and presented a 
high rate of drug release in the diffusional phase over a 
prolonged period (longer than 25 weeks). 
Biodegradable implants in the treatment of uveitis
Dong et al. (2006) developed implants containing 
CsA and the glycolide-co-lactide-co-caprolactone copoly-
mer (PGLC) for the treatment of experimental chronic 
uveitis in rabbit eyes. The results demonstrated that inflam-
mation in eyes with no treatment, non-medicated implant, 
and oral CsA was more severe than in those with CsA-
PGLC DDS at all time points. One group with oral CsA 
administration was intentionally included in this study to 
compare the drug toxicity with the CsA-PGLC implant 
group. The animals that received oral CsA presented se-
vere renal and hepatic insults, which were not observed in 
the other groups. The concentration of CsA released in the 
eyes from the implants was within the therapeutic range 
to suppress inflammation, and no intraocular toxicity was 
evident in the ocular tissues.
Posurdex® (Allergan, USA) is an intravitreal biode-
gradable implant that contains PLGA and dexamethasone 
and is currently undergoing phase III clinical trials. This 
controlled delivery system has been designed for the 
treatment of macular edemas secondary to retinal vein 
occlusion, diabetic macular edema, uveitis, and Irvine-
Gass syndrome (Amo, Urtti, 2008/). Kuppermann and 
coworkers (2007) evaluated the efficacy and safety of 
Posurdex® containing 350 and 700 µg of dexamethasone 
over a 6-month period in 315 patients who presented 
persistent macular edema for at least 90 days. The results 
showed that after 3 months of treatment, 35% and 24% of 
the patients who received 700 µg and 350 µg of dexame-
thasone, respectively, presented an improvement in visual 
acuity. It could therefore be concluded that Posurdex® 
with a higher dose of dexamethasone is more effective 
in treating persistent macular edemas. According to the 
results, depending on the time required for the treatment, 
Posurdex® may be a good option for the management of 
uveitis (Amo, Urtti, 2008).
Recently, Fialho and coworkers developed biodegra-
dable implants containing PLGA and 1000 µg of dexame-
thsone for the treatment of inflammatory diseases in the 
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posterior segment of the eye (Fialho, Silva-Cunha, 2005; 
Fialho et al., 2006). The developed implants were inserted 
into the vitreous of rabbits through pars plana. In vivo 
studies showed that the intravitreous drug concentration 
remained within the therapeutic range during the 8-week 
evaluation period. The system studied was not toxic to 
the normal rabbit retina, and no significant increase in 
intraocular pressure was observed. The satisfactory results 
and the similarity between these implants and PosurdexÒ 
call for further studies regarding the clinical application 
of these systems. 
In a bid to obtain systems that were more easily im-
planted in the eyes without the need for surgical procedures, 
Fialho and coworkers developed biodegradable implants 
similar to those described in the previous paragraph (Fia-
lho et al., 2007), but measuring 8.0 ± 0.3 mm in length and 
0.40 ± 0.03 mm in diameter (Figure 2). These systems were 
implanted into rabbit eyes through a 25-Gauge transcleral 
cannula trocar and released dexamethasone in the vitreous 
within the therapeutic range for more than 3 weeks. These 
systems were not associated with retinal histological chan-
ges or elevated intraocular pressure in normal rabbit eyes.
Fialho et al. also developed poly-e-caprolactone 
(PCL) implants containing dexamethasone (Fialho et 
al., 2008; Fialho et al., 2009). These implants released 
dexamethasone concentrations in vitro, indicating their 
potential for suppressing several inflammatory processes. 
Furthermore, the systems were well tolerated after 30 days 
of implantation in rabbit eyes, evidenced absence of signs 
of inflammatory cells in the vitreous or anterior chamber. 
In the in vivo study, the drug was released within the the-
rapeutic range for 55 weeks after the implantation of the 
system in rabbit eyes.
Kim and coworkers (2008) developed implants 
containing PLA and triamcinolone acetonide (TA). In vivo 
release of the drug was measured in aqueous humor, vi-
treous, and retina-choroid at 1, 2, 4, 8, and 12 weeks after 
intrascleral implantation. TA was detected in aqueous 
humor up to 4 weeks, and in retina–choroid up to 8 we-
eks, after implantation but was detected constantly over 
12 weeks in the vitreous. The possible reason for these 
findings, where the drug was detected for a longer period 
in the vitreous than in the retina, choroids, and aqueous 
humor, may be related to the drug clearance via choroidal 
blood vessels.
Biodegradable implants in the treatment of 
proliferative vitreoretinopathy
Proliferative vitreoretinopathy (PVR) is the process 
in which migration and proliferation of cells occurs in 
the subretinal space, vitreous and retina. PVR involving 
the formation of fibrous membranes, composed of retinal 
pigment epithelial cells, glial cells, macrophages, and 
fibroblasts. Contractile forces generated within the fi-
brous tissue formed ultimately lead to retinal detachment 
and consequent vision loss (Yasukawa et al., 2004). It is 
believed that PVR can be inhibited, thus simultaneously 
preventing the course of the disease, which comprises 
three phases: inflammation, cellular proliferation, and 
healing, leading to retinal traction.
Several studies have reported on the treatment of ex-
perimental PVR in rabbit eyes, focusing on the use of intra-
ocular devices containing different antimetabolites that are 
able to inhibit the cellular proliferation mechanism. Dong 
et al. developed PLGA implants containing 420, 650, and 
1040 µg of all-trans retinoic acid (ar-RA) (Dong et al., 
2006). The implants with the lower concentration of at-
RA failed to inhibit PVR. On the other hand, the implants 
with the higher doses of at-RA presented a satisfactory 
FIGURE 2 - Photography of the biodegradable device that does not require surgical procedure before (A) and after (B) implantation
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antiproliferative effect and released the antimetabolite for 
8 weeks. Nevertheless, despite the inhibition of PVR, the 
release profile of at-RA did not coincide with the cellular 
proliferation pattern.
Rubsamen and coworkers prepared PLGA implants 
containing 5-fluorouracil (5-FU) which provided drug re-
lease within the therapeutic range for 14 days (Rubsamen 
et al., 1994). The retina of eight of the nine rabbits that 
received the polymer with 5-FU, compared to the animal 
that received the control polymer without the drug, remai-
ned attached. No evidence of toxic effects of the drug or 
polymer implant was observed on electroretinographic 
and histopathological studies.
Yasukawa and coworkers (2002) developed im-
plants from blends of PLGA and different concentrations 
of cis-hydroxyproline (CHP). Implants loaded with 20% 
and 15% CHP and made from PLGA (copolymer ratios 
65/35 and 50/50; mean molecular weights of 103000 
and 93000, respectively) were chosen for implantation, 
based on their in vitro release profile. These implants 
proved to be effective in the treatment only during the 
first week because the release rate of the drug and length 
of the diffusional phase were not satisfactory. Therefo-
re, to overcome these problems, two implants (one of 
PLGA 65:35 and the other of PLGA 50:50) were inserted 
simultaneously into rabbit eyes, reducing the incidence 
of retinal detachment from 89% to 57% 28 days after 
implantation. The reduction of the incidence of retinal 
detachment was similar to that observed when 20 µg of 
CHP was directly injected into eyes with induced PVR. 
Implantation with two PLGA 50:50 implants had no 
significant effect on PVR. The results suggest that the 
combined release profiles of different implants are more 
effective in reducing retinal detachment in eyes with 
induced PVR.
POE IV implants (molecular weight = 6900) con-
taining 5-FU or dexamethasone or 5-FU associated with 
dexamethasone, were developed in an attempt to prevent 
experimental PVR in rabbit eyes. The induced PVR 
was clinically classified as follows: grade 0: No PVR; 
grade 1: epiretinal membranes; grade 2: focal traction, 
vessel abnormalities, and tortuosity; grade 3: localized 
retinal detachment; grade 4: extended retinal detachment 
and peripapillary detachment; and grade 5: total retinal 
detachment, fixed folds, and retinal tears. The implants 
containing POE IV alone did not affect the development 
of PVRs graded with scores of 4 and 5. On the other hand, 
PVR grades 2 to 3 were observed in eyes treated with POE 
containing either 1% of 5–FU or 1% of dexamethasone. 
Eyes treated with POE releasing both drugs showed the 
lowest PVR grade (1±0.5), thus demonstrating that the 
combination of the two drugs in POE IV implants was 
more effective in the treatment (Bourges et al., 2006).
Zhou and coworkers (1998) developed PLGA im-
plants containing three drugs: 5-fluorouracil (5-FU, an 
antimetabolite), triamcinolone (Triam, a corticosteroid), 
and human recombinant tissue plasminogen activator (t-
PA, a thrombolytic agent). These drugs prevented PVR 
by three separate mechanisms: (i) inhibiting cellular 
proliferation, (ii) inhibiting the inflammatory response, 
and (iii) inhibiting fibrin matrix formation. In vitro release 
studies showed that 5-FU and Triam were released at a 
rate of 1 mg/day over a 4-week period and 10 to 190 mg/
day over a 2-week period, respectively. After a time lag 
of 2 days, t-PA was released at a rate of 0.2 to 0.5 mg/day 
over a 2-week period. Despite the promising results, the-
se multiple-drug delivery implants require further study 
before clinical application.
Some studies were carried out using intraocular 
implants containing only one antiproliferative drug, while 
other studies used implants containing two or more dru-
gs. The administration of multiple drugs can potentially 
improve the treatment of PVR as the processes of cellular 
proliferation, cellular migration, and membrane synthesis 
can be targeted simultaneously.
Biodegradable implants in the prevention of post-
cataract surgery diseases
The inconvenience related to cataract surgery, such 
as inflammations and infections, if untreated or treated 
late, can prolong patient discomfort and contribute to 
the occurrence of complications, such as macular edema 
and posterior capsular opacification. Prevention has been 
performed with the use of eyedrops containing anti-in-
flammatory and antibiotic drugs. However, drug delivery 
systems are being developed to avoid the use of eyedrops 
and make cataract surgery safer.
SurodexÒ (Oculex Pharmaceuticals, Sunnyvale, 
California) is a monolithic system containing PLGA and 
60 µg of homogeneously dispersed dexamethasone. This 
biodegradable system is used to avoid inflammation after 
cataract surgery. Initially, it was demonstrated that this 
system, implanted in the anterior chamber of rabbit eyes, 
provided controlled release of dexamethasone in zero order 
kinetics over a 7-day period. The safety of this implant was 
demonstrated in phase I toxicological studies (FDA pro-
tocol nº 94001). Studies in humans were later carried out 
to compare the performance of SurodexÒ against eyedrops 
containing 0.1% of dexamethasone, in the eyes of patients 
who had undergone cataract surgery and received intraocu-
lar lens (IOL). The results showed that Surodex® was more 
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effective in reducing post-surgical inflammation (Tan et al., 
1999). Wadood and coworkers also evaluated the safety and 
efficacy of Surodex® versus 0.1% dexamethasone eyedrops 
in patients with inflammation after cataract surgery (Wa-
dood et al., 2004). Once again, Surodex® proved to be more 
effective in controlling intraocular inflammation. Therefore, 
according to these studies, there are three main advantages 
of implants placed in the anterior chamber, as compared to 
eyedrops: (1) a smaller amount of drug used in the formu-
lation and consequent reduction of adverse effects and sys-
temic toxicity; (2) the control of drug release in the anterior 
segment with zero order kinetics; and (3) the reduction of 
complications in patients who use eyedrops incorrectly due 
to low compliance with the therapy. Surodex® is currently 
undergoing phase III clinical studies (Seah et al., 2005).
In another study conducted by Siqueira et al. (2006), 
a delivery system attached to an IOL made of poly (me-
thylmetacrylate) (PMMA) was prepared. The developed 
lens was biconvex, with an optical diameter of 6 mm, total 
diameter of 12.75 mm, Å constant of 118.5, “C” modified 
loops and refraction index of 1.492. At the loops inser-
tion, a ring of 1 mm in diameter was made using the same 
material, and the dexamethasone delivery systems were 
attached to the lens’ rings. The IOL were implanted in 
rabbit eyes. The results of this study showed that the IOL 
containing biodegradable devices promoted an appropriate 
and controlled release of dexamethasone. After 6 days of 
implantation, approximately 1.0 mg/mL and 0.4 mg/mL 
of the drug were released into the aqueous humor and the 
vitreous, respectively. These values are higher than those 
observed in other studies, in which dexamethasone deli-
very systems were implanted into the anterior chamber 
after cataract surgery. Studies aimed at developing folda-
ble IOL containing the drug delivery system are currently 
underway.
CONCLUSIONS
Non-biodegradable intraocular implants present 
the advantage of controlling drug release with predicted 
kinetics over a long period of time. Furthermore, elevated 
concentrations of the drug can be found in the vitreous, 
while small concentrations are detected in the aqueous 
humor and blood. However, in contrast to biodegradable 
implants, these devices must be removed after complete 
drug release, representing a risk for patients and a disad-
vantage of the systems.
Biodegradable implants do not have to be removed 
as they are degraded and absorbed or eliminated from the 
body. This reduces the need for further surgery to remove 
implants after complete drug release, and can increase 
patient compliance with the treatment. However, the 
development of these systems is more complicated when 
compared to non-biodegradable systems as some key 
variables, such as the degradation kinetics of the polymer 
in vivo, must be considered. 
Finally, there are many challenges to consider and 
overcome in order to develop biodegradable implants able 
to provide prolonged drug release within the therapeutic 
range for effective treatment of ocular diseases.
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